{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T04:11:17Z","timestamp":1788754277287,"version":"build-2803163510"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:00:00Z","timestamp":1786147200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100009592","name":"Beijing Municipal Science and Technology Commission","doi-asserted-by":"publisher","award":["Z191100006619112"],"award-info":[{"award-number":["Z191100006619112"]}],"id":[{"id":"10.13039\/501100009592","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82272398"],"award-info":[{"award-number":["82272398"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82472349"],"award-info":[{"award-number":["82472349"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.semarthrit.2026.153054","type":"journal-article","created":{"date-parts":[[2026,8,7]],"date-time":"2026-08-07T06:33:03Z","timestamp":1786084383000},"page":"153054","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China"],"prefix":"10.1016","volume":"80","author":[{"given":"Li","family":"Shanshan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wang","family":"Xiaoxing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liu","family":"Haiyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liang","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duan","family":"Jianghui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lu","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shu","family":"Xiaoming","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0001","doi-asserted-by":"crossref","first-page":"70","DOI":"10.1016\/j.nmd.2019.10.005","article-title":"239th ENMC international workshop: classification of dermatomyositis, Amsterdam, the Netherlands, 14-16 December 2018","volume":"30","author":"Mammen","year":"2020","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0002","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"6","key":"10.1016\/j.semarthrit.2026.153054_bib0003","doi-asserted-by":"crossref","first-page":"3288","DOI":"10.1093\/rheumatology\/keaf116","article-title":"Treatment guidelines for idiopathic inflammatory myopathies in adults: a comparative review","volume":"64","author":"Paik","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153054_bib0004","doi-asserted-by":"crossref","first-page":"1432","DOI":"10.1093\/rheumatology\/kead404","article-title":"Tofacitinib therapy in refractory inflammatory myositis: a retrospective cohort study of 41 patients","volume":"63","author":"Beckett","year":"2024","journal-title":"Rheumatology (Oxford)"},{"issue":"9","key":"10.1016\/j.semarthrit.2026.153054_bib0005","doi-asserted-by":"crossref","first-page":"4948","DOI":"10.1093\/rheumatology\/keaf225","article-title":"Long-term effectiveness and safety of baricitinib treatment on refractory or severe juvenile dermatomyositis","volume":"64","author":"Wang","year":"2025","journal-title":"Rheumatology (Oxford)"},{"issue":"5","key":"10.1016\/j.semarthrit.2026.153054_bib0006","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.01488-2024","article-title":"Effectiveness and safety of tofacitinib versus calcineurin inhibitor in interstitial lung disease secondary to anti-MDA5-positive dermatomyositis: a multicentre cohort study","volume":"65","author":"Wu","year":"2025","journal-title":"Eur Respir J"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0007","doi-asserted-by":"crossref","DOI":"10.1080\/09546634.2024.2391445","article-title":"A case of refractory anti-MDA5-positive amyopathic dermatomyositis successfully treated with upadacitinib","volume":"35","author":"Huang","year":"2024","journal-title":"J Dermatolog Treat"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0008","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2023-003837","article-title":"Upadacitinib therapy in refractory inflammatory myositis: a case series of 10 patients","volume":"10","author":"Beckett","year":"2024","journal-title":"RMD Open"},{"key":"10.1016\/j.semarthrit.2026.153054_bib0009","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jdcr.2024.08.047","article-title":"Case of recalcitrant amyopathic dermatomyositis treated with upadacitinib","volume":"54","author":"Zhou","year":"2024","journal-title":"JAAD Case Rep"},{"key":"10.1016\/j.semarthrit.2026.153054_bib0010","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.jdcr.2024.06.033","article-title":"Successful treatment of refractory amyopathic dermatomyositis with upadacitinib in prior JAK inhibitor failure","volume":"51","author":"Sohn","year":"2024","journal-title":"JAAD Case Rep"},{"issue":"7","key":"10.1016\/j.semarthrit.2026.153054_bib0011","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1111\/ijd.17135","article-title":"A case of refractory amyopathic dermatomyositis successfully treated with upadacitinib","volume":"63","author":"Battocchio","year":"2024","journal-title":"Int J Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153054_bib0012","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 European League Against Rheumatism\/American College of Rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2026.153054_bib0013","article-title":"The role of upadacitinib in refractory dermatomyositis: a systematic review","author":"Srivatsa","year":"2025","journal-title":"J Am Acad Dermatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153054_bib0014","doi-asserted-by":"crossref","first-page":"1625","DOI":"10.1080\/14656566.2024.2392021","article-title":"Current evidence for janus kinase inhibitors in adult and juvenile dermatomyositis and key comparisons","volume":"25","author":"Wallwork","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153054_bib0015","doi-asserted-by":"crossref","first-page":"924","DOI":"10.1016\/j.jaad.2022.10.055","article-title":"JAK inhibitors for the treatment of adult dermatomyositis: a pilot study","volume":"88","author":"Landon-Cardinal","year":"2023","journal-title":"J Am Acad Dermatol"},{"issue":"3","key":"10.1016\/j.semarthrit.2026.153054_bib0016","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1016\/S2213-2600(24)00267-4","article-title":"Idiopathic inflammatory myopathies related lung disease in adults","volume":"13","author":"Sehgal","year":"2025","journal-title":"Lancet Respir Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0017","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1038\/s41584-023-01054-9","article-title":"Anti-MDA5 antibody-positive dermatomyositis: pathogenesis and clinical progress","volume":"20","author":"Lu","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2026.153054_bib0018","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1093\/rheumatology\/key188","article-title":"Tofacitinib for refractory interstitial lung diseases in anti-melanoma differentiation-associated 5 gene antibody-positive dermatomyositis","volume":"57","author":"Kurasawa","year":"2018","journal-title":"Rheumatology (Oxford)"},{"issue":"1","key":"10.1016\/j.semarthrit.2026.153054_bib0019","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1097\/RHU.0000000000002274","article-title":"Prophylaxis with valganciclovir in anti-melanoma differentiation associated 5 gene antibody dermatomyositis: a cohort study in China","volume":"32","author":"Shanshan","year":"2026","journal-title":"J Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2026.153054_bib0020","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1007\/s40265-023-01840-5","article-title":"Safety of Janus Kinase inhibitors in inflammatory bowel diseases","volume":"83","author":"N\u00fa\u00f1ez","year":"2023","journal-title":"Drugs"},{"issue":"2","key":"10.1016\/j.semarthrit.2026.153054_bib0021","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/s41584-023-01062-9","article-title":"Efficacy and safety of JAK inhibitors in rheumatoid arthritis: update for the practising clinician","volume":"20","author":"Szekanecz","year":"2024","journal-title":"Nat Rev Rheumatol"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001447?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017226001447?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T03:59:42Z","timestamp":1788753582000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017226001447"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":21,"alternative-id":["S0049017226001447"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153054","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Effectiveness and safety of upadacitinib on adult dermatomyositis: a cohort study in China","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2026.153054","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}],"article-number":"153054"}}